Amgen Inc. (“Amgen”) appeals an order of the United States District Court for the District of Delaware denying Amgen’s motion to compel discovery from Hospira, Inc. (“Hospira”) in a patent infringement case governed by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), Pub. L. No. 111-148, 124 Stat. 119, 804 (2010) (amending 42 U.S.C. § 262). Amgen alternatively seeks a writ of mandamus ordering the court to compel discovery.
Because we lack jurisdiction over the district court’s order under the collateral order doctrine and find that Amgen fails to satisfy the prerequisites for mandamus, we dismiss the appeal and deny the writ.